FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385969102> ?p ?o ?g. }

• W4385969102 abstract "Background The coronavirus disease 2019 (COVID‐19) pandemic has impacted healthcare systems worldwide. Multiple reports on thromboembolic complications related to COVID‐19 have been published, and researchers have described that people with COVID‐19 are at high risk for developing venous thromboembolism (VTE). Anticoagulants have been used as pharmacological interventions to prevent arterial and venous thrombosis, and their use in the outpatient setting could potentially reduce the prevalence of vascular thrombosis and associated mortality in people with COVID‐19. However, even lower doses used for a prophylactic purpose may result in adverse events such as bleeding. It is important to consider the evidence for anticoagulant use in non‐hospitalised people with COVID‐19. Objectives To evaluate the benefits and harms of prophylactic anticoagulants versus active comparators, placebo or no intervention, or non‐pharmacological interventions in non‐hospitalised people with COVID‐19. Search methods We used standard, extensive Cochrane search methods. The latest search date was 18 April 2022. Selection criteria We included randomised controlled trials (RCTs) comparing prophylactic anticoagulants with placebo or no treatment, another active comparator, or non‐pharmacological interventions in non‐hospitalised people with COVID‐19. We included studies that compared anticoagulants with a different dose of the same anticoagulant. We excluded studies with a duration of under two weeks. Data collection and analysis We used standard Cochrane methodological procedures. Our primary outcomes were all‐cause mortality, VTE (deep vein thrombosis (DVT) or pulmonary embolism (PE)), and major bleeding. Our secondary outcomes were DVT, PE, need for hospitalisation, minor bleeding, adverse events, and quality of life. We used GRADE to assess the certainty of the evidence. Main results We included five RCTs with up to 90 days of follow‐up (short term). Data were available for meta‐analysis from 1777 participants. Anticoagulant compared to placebo or no treatment Five studies compared anticoagulants with placebo or no treatment and provided data for three of our outcomes of interest (all‐cause mortality, major bleeding, and adverse events). The evidence suggests that prophylactic anticoagulants may lead to little or no difference in all‐cause mortality (risk ratio (RR) 0.36, 95% confidence interval (CI) 0.04 to 3.61; 5 studies; 1777 participants; low‐certainty evidence) and probably reduce VTE from 3% in the placebo group to 1% in the anticoagulant group (RR 0.36, 95% CI 0.16 to 0.85; 4 studies; 1259 participants; number needed to treat for an additional beneficial outcome (NNTB) = 50; moderate‐certainty evidence). There may be little to no difference in major bleeding (RR 0.36, 95% CI 0.01 to 8.78; 5 studies; 1777 participants; low‐certainty evidence). Anticoagulants probably result in little or no difference in DVT (RR 1.02, 95% CI 0.30 to 3.46; 3 studies; 1009 participants; moderate‐certainty evidence), but probably reduce the risk of PE from 2.7% in the placebo group to 0.7% in the anticoagulant group (RR 0.25, 95% CI 0.08 to 0.79; 3 studies; 1009 participants; NNTB 50; moderate‐certainty evidence). Anticoagulants probably lead to little or no difference in reducing hospitalisation (RR 1.01, 95% CI 0.59 to 1.75; 4 studies; 1459 participants; moderate‐certainty evidence) and may lead to little or no difference in adverse events (minor bleeding, RR 2.46, 95% CI 0.90 to 6.72; 5 studies, 1777 participants; low‐certainty evidence). Anticoagulant compared to a different dose of the same anticoagulant One study compared anticoagulant (higher‐dose apixaban) with a different (standard) dose of the same anticoagulant and reported five relevant outcomes. No cases of all‐cause mortality, VTE, or major bleeding occurred in either group during the 45‐day follow‐up (moderate‐certainty evidence). Higher‐dose apixaban compared to standard‐dose apixaban may lead to little or no difference in reducing the need for hospitalisation (RR 1.89, 95% CI 0.17 to 20.58; 1 study; 278 participants; low‐certainty evidence) or in the number of adverse events (minor bleeding, RR 0.47, 95% CI 0.09 to 2.54; 1 study; 278 participants; low‐certainty evidence). Anticoagulant compared to antiplatelet agent One study compared anticoagulant (apixaban) with antiplatelet agent (aspirin) and reported five relevant outcomes. No cases of all‐cause mortality or major bleeding occurred during the 45‐day follow‐up (moderate‐certainty evidence). Apixaban may lead to little or no difference in VTE (RR 0.36, 95% CI 0.01 to 8.65; 1 study; 279 participants; low‐certainty evidence), need for hospitalisation (RR 3.20, 95% CI 0.13 to 77.85; 1 study; 279 participants; low‐certainty evidence), or adverse events (minor bleeding, RR 2.13, 95% CI 0.40 to 11.46; 1 study; 279 participants; low‐certainty evidence). No included studies reported on quality of life or investigated anticoagulants compared to a different anticoagulant, or anticoagulants compared to non‐pharmacological interventions. Authors' conclusions We found low‐ to moderate‐certainty evidence from five RCTs that prophylactic anticoagulants result in little or no difference in major bleeding, DVT, need for hospitalisation, or adverse events when compared with placebo or no treatment in non‐hospitalised people with COVID‐19. Low‐certainty evidence indicates that prophylactic anticoagulants may result in little or no difference in all‐cause mortality when compared with placebo or no treatment, but moderate‐certainty evidence indicates that prophylactic anticoagulants probably reduce the incidence of VTE and PE. Low‐certainty evidence suggests that comparing different doses of the same prophylactic anticoagulant may result in little or no difference in need for hospitalisation or adverse events. Prophylactic anticoagulants may result in little or no difference in risk of VTE, hospitalisation, or adverse events when compared with antiplatelet agents (low‐certainty evidence). Given that there were only short‐term data from one study, these results should be interpreted with caution. Additional trials of sufficient duration are needed to clearly determine any effect on clinical outcomes." @default.
• W4385969102 created "2023-08-19" @default.
• W4385969102 creator A5000264599 @default.
• W4385969102 creator A5011139272 @default.
• W4385969102 creator A5023830488 @default.
• W4385969102 creator A5043924180 @default.
• W4385969102 creator A5046301697 @default.
• W4385969102 date "2023-08-16" @default.
• W4385969102 modified "2023-10-07" @default.
• W4385969102 title "Prophylactic anticoagulants for non-hospitalised people with COVID-19" @default.
• W4385969102 cites W1247968195 @default.
• W4385969102 cites W1511757448 @default.
• W4385969102 cites W1946283557 @default.
• W4385969102 cites W1962175700 @default.
• W4385969102 cites W1975757685 @default.
• W4385969102 cites W1992753667 @default.
• W4385969102 cites W2018856451 @default.
• W4385969102 cites W2037377025 @default.
• W4385969102 cites W2054008179 @default.
• W4385969102 cites W2079810642 @default.
• W4385969102 cites W2093829433 @default.
• W4385969102 cites W2104321230 @default.
• W4385969102 cites W2104841305 @default.
• W4385969102 cites W2117983655 @default.
• W4385969102 cites W2128485290 @default.
• W4385969102 cites W2134617967 @default.
• W4385969102 cites W2140707981 @default.
• W4385969102 cites W2150531451 @default.
• W4385969102 cites W2170892587 @default.
• W4385969102 cites W2171357097 @default.
• W4385969102 cites W2225937646 @default.
• W4385969102 cites W2265369351 @default.
• W4385969102 cites W2595086780 @default.
• W4385969102 cites W2888169160 @default.
• W4385969102 cites W2972049715 @default.
• W4385969102 cites W2975307018 @default.
• W4385969102 cites W3003749070 @default.
• W4385969102 cites W3008461878 @default.
• W4385969102 cites W3015656121 @default.
• W4385969102 cites W3015863623 @default.
• W4385969102 cites W3016595631 @default.
• W4385969102 cites W3017014626 @default.
• W4385969102 cites W3017125154 @default.
• W4385969102 cites W3017326650 @default.
• W4385969102 cites W3019953082 @default.
• W4385969102 cites W3021591080 @default.
• W4385969102 cites W3021954309 @default.
• W4385969102 cites W3022903699 @default.
• W4385969102 cites W3023853377 @default.
• W4385969102 cites W3026447494 @default.
• W4385969102 cites W3029923949 @default.
• W4385969102 cites W3031222981 @default.
• W4385969102 cites W3033737540 @default.
• W4385969102 cites W3033845593 @default.
• W4385969102 cites W3036203801 @default.
• W4385969102 cites W3040254875 @default.
• W4385969102 cites W3041992145 @default.
• W4385969102 cites W3045413314 @default.
• W4385969102 cites W3081195961 @default.
• W4385969102 cites W3084150412 @default.
• W4385969102 cites W3090555129 @default.
• W4385969102 cites W3093285817 @default.
• W4385969102 cites W3107284527 @default.
• W4385969102 cites W3112865739 @default.
• W4385969102 cites W3114549062 @default.
• W4385969102 cites W3115566120 @default.
• W4385969102 cites W3122948105 @default.
• W4385969102 cites W3123099249 @default.
• W4385969102 cites W3126183465 @default.
• W4385969102 cites W3128604271 @default.
• W4385969102 cites W3129951990 @default.
• W4385969102 cites W3130133293 @default.
• W4385969102 cites W3132892663 @default.
• W4385969102 cites W3134173039 @default.
• W4385969102 cites W3136081107 @default.
• W4385969102 cites W3137220533 @default.
• W4385969102 cites W3145085216 @default.
• W4385969102 cites W3158378333 @default.
• W4385969102 cites W3169338198 @default.
• W4385969102 cites W3172261555 @default.
• W4385969102 cites W3173920521 @default.
• W4385969102 cites W3174626491 @default.
• W4385969102 cites W3179655344 @default.
• W4385969102 cites W3190946380 @default.
• W4385969102 cites W3194033501 @default.
• W4385969102 cites W3194189472 @default.
• W4385969102 cites W3196997629 @default.
• W4385969102 cites W3200339764 @default.
• W4385969102 cites W3202637221 @default.
• W4385969102 cites W3206483794 @default.
• W4385969102 cites W4200137171 @default.
• W4385969102 cites W4200187357 @default.
• W4385969102 cites W4210486504 @default.
• W4385969102 cites W4210499980 @default.
• W4385969102 cites W4210786653 @default.
• W4385969102 cites W4225684417 @default.
• W4385969102 cites W4226119502 @default.
• W4385969102 cites W4226284367 @default.
• W4385969102 cites W4226407007 @default.
• W4385969102 cites W4283744395 @default.

• next